Highlights & Basics
- Persistent depressive disorder (PDD) includes common forms of depression, but lasting longer than acute major depressive disorder.
- Frequently misdiagnosed because the correct criteria to diagnose this condition are often not applied. Affected patients have a depressed mood most of the day, for more days than not, for at least 2 years. While depressed, patients have at least 2 of: poor appetite/overeating, insomnia or hypersomnia, low energy/fatigue, low self-esteem, poor concentration or difficulty making decisions, or feelings of hopelessness. Symptoms do not remit for more than 2 months at a time.
- Associated with significant functional impairment (including unemployment, difficulty establishing intimate relationships, greater healthcare utilization, greater utilization of public entitlements).
- Patients may respond to pharmacotherapy, psychotherapy, or a combination of both.
- Patients require a longer treatment period, more psychotherapy sessions, and/or higher doses of antidepressants compared with patients with acute forms of depression.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry. 2024 Sep;69(9):641-87.[Abstract][Full Text]
National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication].[Full Text]
Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.[Abstract][Full Text]
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. First MB, Gaebel W, Maj M, et al. An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. 2021 Feb;20(1):34-51.[Abstract][Full Text]
3. International Classification of Diseases 11th Revision. World Health Organization. Feb 2022 [internet publication].[Full Text]
4. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. Geneva: World Health Organization; 2024.[Full Text]
5. Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord. 2012 Jul;139(2):172-80.[Abstract]
6. Nübel J, Guhn A, Müllender S, et al. Persistent depressive disorder across the adult lifespan: results from clinical and population-based surveys in Germany. BMC Psychiatry. 2020 Feb 10;20(1):58.[Abstract][Full Text]
7. Blanco C, Okuda M, Markowitz JC, et al. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010 Dec;71(12):1645-56.[Abstract][Full Text]
8. Vandeleur CL, Fassassi S, Castelao E, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017 Apr;250:50-8.[Abstract]
9. Kessler RC, Berglund PA, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602.[Abstract][Full Text]
10. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):617-27.[Abstract][Full Text]
11. Devanand DP, Nobler MS, Singer T, et al. Is dysthymia a different disorder in the elderly? Am J Psychiatry. 1994 Nov;151(11):1592-9.[Abstract]
12. Devanand DP, Adorno E, Cheng J, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004 Mar;78(3):259-67.[Abstract]
13. Schaakxs R, Comijs HC, Lamers F, et al. Associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. Lancet Psychiatry. 2018 Jul;5(7):581-90.[Abstract]
14. Köhler S, Chrysanthou S, Guhn A, et al. Differences between chronic and nonchronic depression: systematic review and implications for treatment. Depress Anxiety. 2019 Jan;36(1):18-30.[Abstract]
15. Klein DN, Schwartz JE, Rose S, et al. Five-year course and outcome of dysthymic disorder: a prospective, naturalistic follow-up study. Am J Psychiatry. 2000 Jun;157(6):931-9.[Abstract]
16. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry. 2006 May;163(5):872-80.[Abstract][Full Text]
17. Angst J, Gamma A, Rössler W, et al. Long-term depression versus episodic major depression: results from the prospective Zurich study of a community sample. J Affect Dis. 2009 May;115(1-2):112-21.[Abstract]
18. Hellerstein DJ, Agosti V, Bosi M, et al. Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. J Affect Disord. 2010 Dec;127(1-3):84-8.[Abstract]
19. Peterson RE, Cai N, Dahl AW, et al. Molecular genetic analysis subdivided by adversity exposure suggests etiologic heterogeneity in major depression. Am J Psychiatry. 2018 Jun 1;175(6):545-54.[Abstract][Full Text]
20. Klein DN, Shankman SA, Lewinsohn PM, et al. Family study of chronic depression in a community sample of young adults. Am J Psychiatry. 2004 Apr;161(4):646-53.[Abstract][Full Text]
21. Lyons MJ, Eisen SA, Goldberg J, et al. A registry-based twin study of depression in men. Arch Gen Psychiatry. 1998 May;55(5):468-72.[Abstract][Full Text]
22. Khandaker GM, Stochl J, Zammit S, et al. Childhood inflammatory markers and intelligence as predictors of subsequent persistent depressive symptoms: a longitudinal cohort study. Psychol Med. 2018 Jul;48(9):1514-22.[Abstract][Full Text]
23. Harkness KL, Theriault JE, Stewart JG, et al. Acute and chronic stress exposure predicts 1-year recurrence in adult outpatients with residual depression symptoms following response to treatment. Depress Anxiety. 2014 Jan;31(1):1-8.[Abstract]
24. Klein DN, Riso LP, Donaldson SK, et al. Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Arch Gen Psychiatry. 1995 Jun;52(6):487-96.[Abstract]
25. Schramm E, Klein DN, Elsaesser M, et al. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry. 2020 Sep;7(9):801-12.[Abstract]
26. Carpenter LL, Tyrka AR, McDougle CJ, et al. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology. 2004 Apr;29(4):777-84.[Abstract][Full Text]
27. Gray JP, Müller VI, Eickhoff SB, et al. Multimodal abnormalities of brain structure and function in major depressive disorder: a meta-analysis of neuroimaging studies. Am J Psychiatry. 2020 May 1;177(5):422-34.[Abstract][Full Text]
28. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.[Abstract][Full Text]
29. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.[Abstract]
30. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004 Jan;34(1):73-82.[Abstract]
31. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry. 2024 Sep;69(9):641-87.[Abstract][Full Text]
32. Walter HJ, Abright AR, Bukstein OG, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. J Am Acad Child Adolesc Psychiatry. 2023 May;62(5):479-502.[Abstract][Full Text]
33. National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication].[Full Text]
34. McGuinness K, Dutton S, Smith P. Mood disorders: evidence‐based integrated biopsychosocial treatment of dysthymia and adjustment disorder with depression. In: Muse M, ed. Cognitive behavioral psychopharmacology: the clinical practice of evidence‐based biopsychosocial integration. 1st ed. Hoboken, NJ: John Wiley & Sons, 2017; 85-106.
35. US Preventive Services Task Force. Screening for depression and suicide risk in adults: US Preventive Services Task Force recommendation statement. JAMA. 2023 Jun 20;329(23):2057-67.[Abstract][Full Text]
36. Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC): part I. Practice preparation, identification, assessment, and initial management. Pediatrics. 2018 Mar;141(3):e20174081.[Abstract][Full Text]
37. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Screening for depression and suicide risk in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2022 Oct 18;328(15):1534-42.[Abstract][Full Text]
38. Lang E, Gray C, LeBlanc JC, et al. Recommendation on screening adults for depression using a screening tool. CMAJ. 2025 Oct 19;197(35):E1132-43.[Abstract][Full Text]
39. National Institute for Health and Care Excellence (NICE). Depression in adults: evidence review E - chronic depression. NICE Guideline No. 222. London: NICE; 2022.[Full Text]
40. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18;342(20):1462-70.[Abstract][Full Text]
41. Cuijpers P, Sijbrandij M, Koole SL, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013 Jun;12(2):137-48.[Abstract][Full Text]
42. Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010 Oct;27(10):891-932.[Abstract][Full Text]
43. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020 Feb;19(1):92-107.[Abstract][Full Text]
44. Cuijpers P, Miguel C, Harrer M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023 Feb;22(1):105-15.[Abstract][Full Text]
45. US Department of Veterans Affairs. VA/DOD clinical practice guidelines: management of major depressive disorder (MDD) (2022). Feb 2022 [internet publication].[Full Text]
46. Furukawa TA, Efthimiou O, Weitz ES, et al. Cognitive-behavioral analysis system of psychotherapy, drug, or their combination for persistent depressive disorder: personalizing the treatment choice using individual participant data network metaregression. Psychother Psychosom. 2018;87(3):140-53.[Abstract]
47. Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC): part II. Treatment and ongoing management. Pediatrics. 2018 Mar;141(3):e20174082.[Abstract][Full Text]
48. Smith SM, Cousins G, Clyne B, et al. Shared care across the interface between primary and specialty care in management of long term conditions. Cochrane Database Syst Rev. 2017 Feb 23;2:CD004910.[Abstract][Full Text]
49. Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med. 2014 Jan;76(1):29-37.[Abstract][Full Text]
50. Van Leeuwen WE, Unutzer J, Lee S, et al. Collaborative depression care for the old-old: findings from the IMPACT trial. Am J Geriatr Psychiatry. 2009 Dec;17(12):1040-9.[Abstract]
51. Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. BMJ. 2006 Feb 4;332(7536):259-63.[Abstract][Full Text]
52. Interian A, Lewis-Fernández R, Gara MA, et al. A randomized-controlled trial of an intervention to improve antidepressant adherence among Latinos with depression. Depress Anxiety. 2013 Jul;30(7):688-96.[Abstract]
53. Gartlehner G, Wagner G, Matyas N, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open. 2017 Jun 14;7(6):e014912.[Abstract][Full Text]
54. McCullough JP. Psychotherapy for dysthymia. A naturalistic study of ten patients. J Nerv Ment Dis. 1991 Dec;179(12):734-40.[Abstract]
55. Brakemeier EL, Herzog P, Radtke M, et al. CBASP as an inpatient concept for treatment-resistant chronic depression: a pilot study of the relationship between adverse effects and treatment outcome. [in ger]. Psychother Psychosom Med Psychol. 2018 Sep;68(9-10):399-407.[Abstract]
56. Kocsis JH, Gelenberg AJ, Rothbaum AO, et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP trial. Arch Gen Psych. 2009 Nov;66(11):1178-88.[Abstract][Full Text]
57. Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for pure dysthymic patients. J Affect Disord. 2005 Dec;89(1-3):167-75.[Abstract]
58. Kriston L, von Wolff A, Westphal A, et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014 Aug;31(8):621-30.[Abstract]
59. Linde K, Sigterman K, Kriston L, et al. Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med. 2015 Jan-Feb;13(1):56-68.[Abstract][Full Text]
60. Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012 Oct;60(10):1817-30.[Abstract]
61. Arnarson EO, Craighead WE. Prevention of depression among Icelandic adolescents: a 12-month follow-up. Behav Res Ther. 2011 Mar;49(3):170-4.[Abstract]
62. Clarke GN, Hornbrook M, Lynch F, et al. A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatry. 2001 Dec;58(12):1127-34.[Abstract][Full Text]
63. Viswanathan M, Kennedy SM, McKeeman J, et al. Treatment of depression in children and adolescents: a systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2020 Apr.[Abstract][Full Text]
64. Liang JH, Li J, Wu RK, et al. Effectiveness comparisons of various psychosocial therapies for children and adolescents with depression: a Bayesian network meta-analysis. Eur Child Adolesc Psychiatry. 2021 May;30(5):685-97.[Abstract]
65. Zhou X, Teng T, Zhang Y, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jul;7(7):581-601.[Abstract][Full Text]
66. Eckshtain D, Kuppens S, Ugueto A, et al. Meta-analysis: 13-year follow-up of psychotherapy effects on youth depression. J Am Acad Child Adolesc Psychiatry. 2020 Jan;59(1):45-63.[Abstract]
67. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. J Clin Psych. 2011 Apr;72(4):509-14.[Abstract]
68. von Wolff A, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013 Jan 10;144(1-2):7-15.[Abstract]
69. Cuijpers P, van Straten A, Schuurmans J, et al. Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev. 2010 Feb;30(1):51-62.[Abstract]
70. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA. 2003 Nov 25;100(24):14293-6.[Abstract][Full Text]
71. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996 Sep;53(9):777-84.[Abstract]
72. Devanand DP, Nobler MS, Cheng J, et al. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. Am J Geriatr Psychiatry. 2005 Jan;13(1):59-68.[Abstract]
73. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. Am J Psychiatry. 1993 Aug;150(8):1169-75.[Abstract]
74. Ravindran AV, Cameron C, Bhatla R, et al. Paroxetine in the treatment of dysthymic disorder without co-morbidities: a double-blind, placebo-controlled, flexible-dose study. Asian J Psychiatr. 2013 Apr;6(2):157-61.[Abstract]
75. Hellerstein DJ, Batchelder S, Kreditor D, et al. Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol. 2001 Jun;21(3):325-9.[Abstract]
76. Dunner DL, Hendrickson HE, Bea C, et al. Venaflaxine in dysthymic disorder. J Clin Psychiatry.1997 Dec;58(12):528-31.[Abstract]
77. Dunner DL, Hendrickson HE, Bea C, et al. Dysthymic disorder: treatment with citalopram. Depress Anxiety. 2002;15(1):18-22.[Abstract]
78. Dunner DL, Hendrickson HE, Bea C, et al. Dysthymic disorder: treatment with mirtazapine. Depress Anxiety. 1999;10(2):68-72.[Abstract]
79. Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62(suppl 6):22-29.[Abstract]
80. Komossa K, Depping AM, Gaudchau A, et al. Second generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010 Dec 8;2010(12):CD008121.[Abstract][Full Text]
81. Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021 May 24;5(5):CD013674.[Abstract][Full Text]
82. Cox GR, Fisher CA, De Silva S, et al. Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. Cochrane Database Syst Rev. 2012 Nov 14;11:CD007504.[Abstract][Full Text]
83. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96.[Abstract]
84. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006 Mar;63(3):332-9.[Abstract][Full Text]
85. Iovieno N, Tedeschini E, Bentley KH, et al. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug;72(8):1144-51.[Abstract]
86. Pedrelli P, Iovieno N, Vitali M, et al. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct;31(5):582-6.[Abstract]
87. Levin FR, Mariani J, Brooks DJ, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013 Jun;108(6):1084-94.[Abstract]
88. Raby WN, Rubin EA, Garawi F, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict. 2014 Jan-Feb;23(1):68-75.[Abstract]
89. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD007503.[Abstract][Full Text]
90. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003 Jun 18;289(23):3106-16.[Abstract][Full Text]
91. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010 Apr 12;170(7):600-8.[Abstract][Full Text]
92. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007 Jun;190:460-6.[Abstract][Full Text]
93. Arnold LM, Sarzi-Puttini P, Arsenault P, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study. J Rheumatol. 2015 Jul;42(7):1237-44.[Abstract]
94. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998 Nov 18;280(19):1665-72.[Abstract][Full Text]
95. Machmutow K, Meister R, Jansen A, et al. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database Syst Rev. 2019 May 20;(5):CD012855.[Abstract][Full Text]
96. Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.[Abstract][Full Text]
97. Xie Y, Wu Z, Sun L, et al. The effects and mechanisms of exercise on the treatment of depression. Front Psychiatry. 2021 Nov 5:12:705559.[Abstract][Full Text]
98. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024 Feb 14;384:e075847.[Abstract][Full Text]
99. Clegg AJ, Hill JE, Mullin DS, et al. Exercise for depression. Cochrane Database Syst Rev. 2026 Jan 8;1(1):CD004366.[Abstract][Full Text]
100. Hoffman BM, Babyak MA, Craighead E, et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med. 2011 Feb-Mar;73(2):127-33.[Abstract]
101. Röhricht F, Papadopoulos N, Priebe S. An exploratory randomized controlled trial of body psychotherapy for patients with chronic depression. J Affect Disord. 2013 Oct;151(1):85-91.[Abstract]
102. Köhler-Forsberg O, Cusin C, Nierenberg AA. Evolving issues in the treatment of depression. JAMA. 2019 Jun 25;321(24):2401-2.[Abstract][Full Text]
103. Smith CA, Armour M, Lee MS, et al. Acupuncture for depression. Cochrane Database Syst Rev. 2018 Mar 4;3:CD004046.[Abstract][Full Text]
104. Josephine K, Josefine L, Philipp D, et al. Internet- and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. J Affect Disord. 2017 Dec 1;223:28-40.[Abstract]
105. National Institute for Health and Care Excellence. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment. Sep 2023 [internet publication].[Full Text]
106. Nieuwenhuijsen K, Verbeek JH, Neumeyer-Gromen A, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev. 2020 Oct 13;10(10):CD006237.[Abstract][Full Text]
107. Steffens DC. Treatment-resistant depression in older adults. N Engl J Med. 2024 Feb 15;390(7):630-9.[Abstract][Full Text]
108. Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N Engl J Med. 2023 Mar 23;388(12):1067-79.[Abstract][Full Text]
109. Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD010557.[Abstract][Full Text]
110. LaRocco-Cockburn A, Reed SD, Melville J, et al. Improving depression treatment for women: integrating a collaborative care depression intervention into OB-GYN care. Contemp Clin Trials. 2013 Nov;36(2):362-70.[Abstract]
111. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol. 2006 May;16(4):281-7.[Abstract]
112. Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013 Oct;23(10):1219-25.[Abstract]
113. Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999 Jun 15;45(12):1533-41.[Abstract]
114. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005 Feb;62(2):154-62.[Abstract][Full Text]
115. Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008 Jul;33(4):331-43.[Abstract][Full Text]
116. Anderson DJ, Vazirnia P, Loehr C, et al. Testosterone replacement therapy in the treatment of depression. Health Psychol Res. 2022 Nov 26;10(4):38956.[Abstract][Full Text]
117. Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019 Jan 1;76(1):31-40.[Abstract][Full Text]
118. Shores MM, Kivlahan DR, Sadak TI, et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009 Jul;70(7):1009-16.[Abstract]
119. Bhasin S, Seidman S, Travison TG, et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1814-26.[Abstract][Full Text]
120. Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) concernant l'utilisation de la kétamine racémique chez les adultes souffrant de trouble dépressif majeur. Can J Psychiatry. 2021 Feb;66(2):113-25.[Abstract][Full Text]
121. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021 May 1;178(5):383-99.[Abstract][Full Text]
122. Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612.[Abstract][Full Text]
123. Loo C, Glozier N, Barton D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry. 2023 Dec;223(6):533-41.[Abstract][Full Text]
124. Glue P, Loo C, Fam J, et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024 Jul;30(7):2004-9.[Abstract][Full Text]
125. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021 Jan 1;278:542-55.[Abstract][Full Text]
126. Terao I, Tsuge T, Endo K, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2024 Feb 1;346:49-56.[Abstract]
127. Rosenblat JD, Husain MI, Lee Y, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder. Can J Psychiatry. 2023 Jan;68(1):5-21.[Abstract][Full Text]
128. Kalfas M, Taylor RH, Tsapekos D, et al. Psychedelics for treatment resistant depression: are they game changers? Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2117-32.[Abstract][Full Text]
129. Njenga C, Ramanuj PP, de Magalhães FJC, et al. New and emerging treatments for major depressive disorder. BMJ. 2024 Jul 8;386:e073823.[Abstract][Full Text]
130. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022 Nov 3;387(18):1637-48.[Abstract][Full Text]
131. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb;235(2):399-408.[Abstract][Full Text]
132. Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser. 2016 Mar 1;16(5):1-66.[Abstract][Full Text]
133. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022 Feb;179(2):132-41.[Abstract][Full Text]
134. Philip NS, Brunoni AR. Beyond the primary outcome: why the RECOVER trial for vagus nerve stimulation matters in treatment-resistant depression. Brain Stimul. 2025 May-Jun;18(3):619-21.[Abstract][Full Text]
135. Kavakbasi E, Kraus C, Reif-Leonhard C, et al. Titration of vagus nerve stimulation for difficult-to-treat depression and onset of response: early insights from the RESTORE-LIFE study. J Affect Disord. 2025 Jun 1;378:39-46.[Abstract][Full Text]
136. Rush AJ, Conway CR, Aaronson ST, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: findings from a one-year, randomized, sham-controlled trial. Brain Stimul. 2025 May-Jun;18(3):690-700.[Abstract][Full Text]
137. Silverman JJ, Galanter M, Jackson-Triche M, et al. The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults. Am J Psychiatry. 2015 Aug 1;172(8):798-802.[Abstract]
138. National Institute for Health and Care Excellence. Depression in children and young people: identification and management. June 2019 [internet publication].[Full Text]
139. Moitra M, Santomauro D, Degenhardt L, et al. Estimating the risk of suicide associated with mental disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2021 May;137:242-9.[Abstract][Full Text]
140. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ. 2018 May 23;361:k1951.[Abstract][Full Text]
141. Carpenter DJ, Fong R, Kraus JE, et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry. 2011 Nov;72(11):1503-14.[Abstract]
142. Möller HJ, Baldwin DS, Goodwin G, et al. Do SSRIs or antidepressants in general increase suicidality? WPA section on pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258 Suppl 3:3-23.[Abstract]
143. Li K, Zhou G, Xiao Y, et al. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. Front Psychiatry. 2022 May 26:13:880496.[Abstract][Full Text]
144. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002 Oct;36(10):1577-89.[Abstract]
145. Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry. 1986 May;47(5):225-9.[Abstract]
146. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013 Apr;69(4):755-60.[Abstract]
147. Straley CM, Sochacki M, Reed E, et al. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study. J Affect Disord. 2022 Jan 1;296:476-84.[Abstract]
148. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003 Feb 22;361(9358):653-61.[Abstract]
